Table 3.
Univariate and multivariate analysis of clinicopathological and genetic factors predicting cancer-specific survival
|
Univariate analysis | ||||
|---|---|---|---|---|
| Category | HR1 | 95% CI2 | P | |
| Clinical and pathological factors | ||||
| Age (yrs) |
≥ 72 vs. < 72 |
1.183 |
0.790 - 1.772 |
0.415 |
| Gleason score |
≥ 9 vs. < 9 |
1.759 |
1.151 – 2.687 |
0.009 |
| PSA (ng/mL) |
≥ 260 vs. < 260 |
1.510 |
0.992 – 2.299 |
0.054 |
| HGB (g/dL) |
< 11.5 vs. ≥ 11.5 |
2.251 |
1.261 – 4.019 |
0.006 |
| ALP (IU/L) |
≥ 350 vs. < 350 |
2.836 |
1.756 – 4.578 |
0.00002 |
| LDH (IU/L) |
≥ 500 vs. < 500 |
2.638 |
1.442 – 4.829 |
0.002 |
| Genetic factors |
|
|
|
|
| LD block 1 (CA repeat) |
19 rpts (+) vs. (-) |
1.671 |
1.109 – 2.518 |
0.014 |
| LD block 2 (rs12423791) |
GC + CC vs. GG |
1.658 |
1.102 – 2.495 |
0.015 |
| LD block 3 (haplotype) |
C-T (+) vs. C-T (-) |
2.054 |
1.373 – 3.075 |
0.0005 |
| Number of risk factors |
0 vs. 1–2 vs. 3 |
1.578 |
1.208 – 2.060 |
0.0008 |
| 0–2 vs. 3 |
2.202 |
1.414 – 3.430 |
0.0005 |
|
|
Multivariate analysis |
|
|
|
|
| Full model |
|
|
|
|
| Age (yrs) |
≥ 72 vs. < 72 |
0.919 |
0.554 – 1.526 |
0.745 |
| Gleason score |
≥ 9 vs. < 9 |
1.766 |
1.052 – 2.966 |
0.031 |
| PSA (ng/mL) |
≥ 265 vs. < 265 |
0.932 |
0.496 – 1.749 |
0.826 |
| HGB (g/dL) |
< 11.5 vs. ≥ 11.5 |
2.012 |
0.968 – 4.180 |
0.061 |
| ALP (IU/L) |
≥ 350 vs. < 350 |
2.598 |
1.483 – 4.551 |
0.0008 |
| LDH (IU/L) |
≥ 500 vs. < 500 |
1.836 |
0.977 – 3.448 |
0.059 |
| LD Block 3 (haplotype) |
C-T (+) vs. C-T (-) |
2.619 |
1.559 – 4.399 |
0.0003 |
| Reduced model |
|
|
|
|
| Gleason score |
≥ 9 vs. < 9 |
1.709 |
1.054 – 2.771 |
0.030 |
| HGB (g/dL) |
< 11.5 vs. ≥ 11.5 |
2.082 |
1.113 – 3.897 |
0.022 |
| ALP (IU/L) |
≥ 350 vs. < 350 |
2.819 |
1.695 – 4.689 |
0.00007 |
| LD Block 3 (haplotype) | C-T (+) vs. C-T (-) | 2.626 | 1.603 – 4.305 | 0.0001 |
1HR, hazard ratio; 295% CI, 95% confidence interval.